F-652 is under clinical development by Evive Biotech and currently in Phase II for Acute Liver Failure. According to GlobalData, Phase II drugs for Acute Liver Failure does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the F-652 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
F-652 overview
F-652 is under development for the treatment of moderate to severe covid-19, acute pancreatitis, chronic acute liver failure, alcoholic hepatitis and graft versus host disease (GVHD). It is administered intravenously. It is a recombinant fusion protein containing a recombinant human interleukin 22-human immunoglobulin Fc fusion protein. The drug candidate targets interleukin-22 receptors. The drug candidate is developed based on DiKine technology. It was also under development for the treatment of inflammation and fatty liver disease and moderate to severe coronavirus disease 2019 (COVID-19).
It was also under development for the treatment of covid-19 pneumonia.
Evive Biotech overview
Evive Biotech formerly Generon (Shanghai) is a biotechnology company that offers research and development of therapeutic biologics. The company discovers, develops and produces biomedicines. Its pipeline products comprise F-627, F-652, F-899 and ITabs. Evive Biotech’s F-627 is a recombinant fusion protein with human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. The company’s F-637 is under development, which is intended to treat inflammatory diseases with tissue injuries and immunologic disorders; and F-899, under development, which is intended to treat patients with growth deficiency and wasting diseases. Its ITabs platform all together binds to CD3 molecules on human T cells and to specific tumor antigens. Evive Biotech is headquartered in Shanghai, China.
For a complete picture of F-652’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
